Equity Overview
Price & Market Data
Price: $32.76
Daily Change: -$0.04 / 0.12%
Range: $31.88 - $33.46
Market Cap: $2,513,792,512
Volume: 609,220
Performance Metrics
1 Week: 3.54%
1 Month: 10.15%
3 Months: -7.25%
6 Months: -21.78%
1 Year: -13.70%
YTD: -16.43%
Company Details
Employees: 327
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.